Medco and FDA to collaborate on pharmacogenomics
The groups have signed a two-year agreement.
Pharmacy benefit manager Medco and the Food and Drug Administration have signed a two-year agreement to develop pharmacogenomics research projects to study genetic testing and the effect of genetics on prescription drugs.
The research will initially focus on the blood-thinner warfarin but may later include oncology and virology. Medco and the FDA hope the research will help health professionals better select medications and dosages for individual patients.
To see more Daily News articles, click here.
To go to the Drug Topics homepage, clickhere.
Recent Videos
Related Content
